id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-268389-0agwvsrv	Kaminski, Monica A.	Tocilizumab Therapy of COVID-19: A Comparison of Subcutaneous and Intravenous Therapies	2020-09-28		.txt	text/plain	3416	116	36	More patients in the IV group received Supportive treatment with tocilizumab for COVID-19: A systematic review Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China Detectable serum SARS-Co-V-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort Tocilizumab in patients with severe COVID-19: a retrospective cohort study Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T Cell-induced severe or life-threatening cytokine release syndrome Current concepts in the diagnosis and management of cytokine release syndrome Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19. At the time of IV tocilizumab therapy, 36 (55%) patients met grade 3 and 27 (42%)	cache/cord-268389-0agwvsrv.txt	txt/cord-268389-0agwvsrv.txt
